FDA Sets 2026 Decision Clock for INOVIO’s Rare Disease Therapy
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) said the U.S. Food and Drug Administration has accepted its Biologics License Application for INO-3107, a potential non-surgical treatment for adults with recurrent …
FDA Sets 2026 Decision Clock for INOVIO’s Rare Disease Therapy Read More